April 5th 2025
The authors examine the risks of extractables and leachables, and present solutions that emphasize the importance of a strategic, multi-prong approach.
There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.
Sieve Use in the Pharmaceutical Industry
May 1st 2005Asieve or screener is an essential part of every pharmaceutical production process, particularly as product quality and integrity are so important. The use of a sieve gets rid of oversized contamination to ensure that ingredients and finished products are quality assured during production and before use or despatch.
Transforming Development Productivity Using Integrated Automation
May 1st 2005The FDA initiative —Process Analytical Technologies (PAT) — is slowly gaining momentum, creating a revolution in manufacturing and testing processes that aims to ensure product quality. Its growth will encourage faster testing techniques to bring analytical testing closer to on- and at-line testing during the product manufacturing process.
Glass Reactor Vessel — Value Sealing Innovation
May 1st 2005Active pharmaceutical ingredients (APIs) have become more potent, therefore the requirements of good manufacturing practice (GMP) are making ever more stringent demands on valve design and sealing. An absence of dead space, ease of cleaning and flushing is the norm for valves where cross contamination must be avoided at all costs. Sealing valves to glass reaction vessels has lagged behind valve sealing for steel vessels.
The Sector Chart: A New Engineering Graph for Pharmaceutical Processes
April 2nd 2005The author proposes a new analytical graphic, the sector chart, which presents data that cannot be adequately presented with current graphs.This chart combines features of zone charts with the basic principle of precontrol charts. It addresses engineering control and is superior for representing data such as beneficial and adverse trends.
X-ray Microtomography of Solid Dosage Forms
April 2nd 2005X-ray microtomography has great potential for improving the understanding of the structural features of solid dosage forms and the changes in those features during manufacturing, handling, and storage.This article describes the basic principles of the technique and provides examples of its potential applications.
X-ray Microtomography of Solid Dosage Forms
April 1st 2005X-ray microtomography has great potential for improving the understanding of the structural features of solid dosage forms and the changes in those features during manufacturing, handling, and storage. This article describes the basic principles of the technique and provides examples of its potential applications.
Validation of Alternative Microbiology Methods for Product Testing
April 1st 2005The validation of alternative microbiological testing is an opportunity for a manufacturer to decrease the amount of time required for laboratory results. To properly validate these alternatives, a practitioner must first identify what is being studied. The regulatory effect on established product and process specifications and levels must be completely evaluated, as changing the method of analysis may well change the apparent number in the sample.
Toward a Generic Approach for Stress Testing of Drug Substances and Drug Products
February 2nd 2005The Impurity Profiling Group reviews stress testing according to regulatory guidance documents. The authors emphasize what should be considered for late clinical phases and for registration application dossiers.
Comparison of EP "Heavy Metals" Test with USP "Conductivity" Test
January 2nd 2005Comparative studies of the US Pharmacopeia (645) "Conductivity" and the European Pharmacopeia "Heavy Metals" tests were conducted to demonstrate that the USP method can determine the presence or absence of heavy metals in process water samples.
Acceptable Analytical Practices for Dissolution Testing of Poorly Soluble Compounds
December 2nd 2004This article provides guidance for developing dissolution testing for poorly soluble compounds. It is the second of a series of articles based on material from a 2003 PhRMA workshop about acceptable analytical practices.